Tiopronin is a Small Molecule owned by Mission Pharmacal, and is involved in 1 clinical trial, which was completed.

Tiopronin is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of Tiopronin-cysteine, which is more water-soluble than cystine and is readily excreted. Thus, in patients with cystinuria, sufficient amount of Tiopronin or its active metabolites could appear in urine to react with cystine, lowering cystine excretion.

The revenue for Tiopronin is expected to reach a total of $721m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tiopronin NPV Report.

Tiopronin is currently owned by Mission Pharmacal. Travere Therapeutics is the other company associated in development or marketing of Tiopronin.

Tiopronin Overview

Tiopronin (Thiola) is a thiol compound used as a hepatoprotective agent. It is formulated as coated tablets and tablets for oral route of administration. Thiola is indicated for the improvement of liver function in chronic liver disease, early senile cortical cataracts, mercury excretion increase at the time of mercury poisoning and cystinuria. Thiola also indicated for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. The new formulation of the drug candidate is under development for the treatment of cystinuria.

Travere Therapeutics Overview

Travere Therapeutics, formerly Retrophin, is a biopharmaceutical company that discovers, develops, acquires, and markets drugs for the treatment of rare diseases. The company’s products include thiola, chenodal and cholbam. It develops drugs for therapies to people living with rare kidney, liver, and metabolic diseases. Travere Therapeutics pipeline products include sparsentan, used for the treatment of focal segmental glomerulosclerosis; RE-024, a product candidate to treat pantothenate kinase-associated neurodegeneration and RE-034, utilized for the treatment of severe rare diseases. The company markets its products through its distribution partners. It works in partnership with academia and independent researchers to support the development of novel solutions. Travere Therapeutics is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$227.5 million for the fiscal year ended December 2021 (FY2021), an increase of 14.7% over FY2020. The operating loss of the company was US$161.8 million in FY2021, compared to an operating loss of US$176.2 million in FY2020. The net loss of the company was US$180.1 million in FY2021, compared to a net loss of US$169.4 million in FY2020. The company reported revenues of US$53.5 million for the third quarter ended September 2022, a decrease of 1.2% over the previous quarter.

Quick View – Tiopronin

Report Segments
  • Innovator (NME)
Drug Name
  • Tiopronin
Administration Pathway
  • Oral
Therapeutic Areas
  • Gastrointestinal
  • Genetic Disorders
  • Toxicology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.